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Abstract
Background: The homeobox B13 (HOXB13) G84E mutation has been recommended for use in genetic
counselling for prostate cancer (PCa), but the magnitude of PCa risk conferred by this mutation is
uncertain.
Objective: To obtain precise risk estimates for mutation carriers and information on how these vary by
family history and other factors.
Design, setting, and participants: Two-fold: a systematic review and meta-analysis of published risk
estimates, and a kin-cohort study comprising pedigree data on 11 983 PCa patients enrolled during
1993–2014 from 189 UK hospitals and who had been genotyped for HOXB13 G84E.
Outcome measurements and statistical analysis: Relative and absolute PCa risks. Complex segregation
analysis with ascertainment adjustment to derive age-speciﬁc risks applicable to the population, and to
investigate how these vary by family history and birth cohort.
Results and limitations: A meta-analysis of case-control studies revealed signiﬁcant heterogeneity
between reported relative risks (RRs; range: 0.95–33.0, p < 0.001) and differences by case selection
(p = 0.007). Based on case-control studies unselected for PCa family history, the pooled RR estimate was
3.43 (95% conﬁdence interval [CI] 2.78–4.23). In the kin-cohort study, PCa risk for mutation carriers varied
by family history (p < 0.001). There was a suggestion that RRs decrease with age, but this was not
signiﬁcant (p = 0.068). We found higher RR estimates for men from more recent birth cohorts (p = 0.004):
3.09 (95% CI 2.03–4.71) for men born in 1929 or earlier and 5.96 (95% CI 4.01–8.88) for men born in 1930 or
later. The absolute PCa risk by age 85 for a male HOXB13 G84E carrier varied from 60% for those with no PCa
family history to 98% for those with two relatives diagnosed at young ages, compared with an average risk
of 15% for noncarriers. Limitations include the reliance on self-reported cancer family history.
Conclusions: PCa risks for HOXB13 G84E mutation carriers are heterogeneous. Counselling should not be
based on average risk estimates but on age-speciﬁc absolute risk estimates tailored to individual
mutation carriers’ family history and birth cohort.
Patient summary: Men who carry a hereditary mutation in the homeobox B13 (HOXB13) gene have a
higher than average risk for developing prostate cancer. In our study, we examined a large number of
families of men with prostate cancer recruited across UK hospitals, to assess what other factors may
contribute to this risk and to assess whether we could create a precise model to help in predicting a
man's prostate cancer risk. We found that the risk of developing prostate cancer in men who carry this
genetic mutation is also affected by a family history of prostate cancer and their year of birth. This
information can be used to assess more personalised prostate cancer risks to men who carry HOXB13
mutations and hence better counsel them on more personalised risk management options, such as
tailoring prostate cancer screening frequency.
© 2018 The Authors. Published by Elsevier B.V. on behalf of European Association of Urology. This is an
open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).uted equally.
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The homeobox B13 (HOXB13) gene is involved in prostate
development [1], and in vitro results have suggested that its
transcription factor is involved in prostate cancer (PCa) cell
growth through androgen receptor interaction, regulation by
FOXA1, and other pathways [2]. The HOXB13 missense mutation
G84E is a founder mutation in Nordic populations [3], with
reported carrier frequencies of 0.2–1.4% [4–7], and is carried by
0.1–0.5% in other Western European populations [4,8]. Muta-
tion carrier frequencies are lower in Southern European
populations [4,9], and the variant is very rare in African and
Asian ancestry populations [4,9,10]. HOXB13 G84E is associated
with PCa risk, but reported relative risks (RRs) have shown
considerable heterogeneity and often wide confidence inter-
vals (CIs) [3–22]. Most risk estimates come from case-control
studies, but because G84E mutations are rare, the small
number of mutations in controls can lead to imprecision.
Moreover, estimates may be biased if participants are not
randomly recruited from cases unselected for age at diagnosis
or family history, and if population-matched controls are not
available. In contrast, kin-cohort or family-based  studies, in
which affected individuals are screened for the mutation and
data on relatives are used to estimate cancer risks, enable
observation of a larger number of mutation carriers, and often
provide greater precision and unbiased estimates provided
analyses are adjusted for ascertainment [23–25].
Genetic counselling for men at an elevated PCa risk has
relied predominantly on family history, ethnicity [26], and
BRCA1 or BRCA2 mutation carrier status [27]. Recently, a
consensus conference recommended additionally testing
for HOXB13 mutations [28]. However, to provide individu-
alised counselling to mutation carriers, it is important to
have valid and precise age-specific cancer risk estimates
and information on how other factors including PCa family
history modify these risks.
The aim of the present analysis was two-fold. First, we
performed a systematic review and meta-analysis of the PCa
risk for HOXB13 G84E carriers based on case selection and
study ascertainment criteria. Previous meta-analyses
[29,30] combined RR estimates from unselected and
high-risk cases, resulting in pooled estimates that may
not be widely applicable. Second, using family data from the
largest kin-cohort PCa study to date in which participants
were genotyped for HOXB13 G84E, we estimated relative
and absolute PCa risks for mutation carriers, and assessed
how PCa risks vary by family history, birth cohort, and age.
We used the results to obtain clinically relevant absolute
risk estimates by various PCa family history configurations,
applicable to mutation carriers identified in different
contexts, for example, in clinical genetics or through
population-based screening programmes.
2. Patients and methods
2.1. Systematic review and meta-analysis
We performed a systematic review and meta-analysis to synthesise the
available evidence on HOXB13 G84E mutation and PCa risk. Details arePlease cite this article in press as: Nyberg T, et al. Homeobox B13 G8
doi.org/10.1016/j.eururo.2018.11.015given in the Supplementary material (systematic review and meta-
analysis).
2.2. Risk estimation
2.2.1. Study participants: the United Kingdom Genetic Prostate
Cancer Study
Between January 1993 and November 2014, men diagnosed with
histologically conﬁrmed PCa at one of 189 UK hospitals were recruited
into the three arms of the United Kingdom Genetic Prostate Cancer Study
(UKGPCS). The population-based PRM arm invited all men diagnosed or
treated at the Royal Marsden NHS Foundation Trust. The young-onset
PRY arm invited men diagnosed at age 60. The family-based PRS arm
comprised men from families with at least two PCa cases, one of whom
was diagnosed at age 65, or three family members diagnosed at any
age. Probands provided a saliva or blood sample for genotyping and
information on cancer family history through a questionnaire. Clinical
data were provided by the participants’ healthcare providers.
We included families of probands genotyped for the HOXB13 G84E
mutation. To ensure consistency with sequential ascertainment rules
[31] to obtain unbiased risk estimates, the analysis was based on
systematically collected data from the proband, ﬁrst-degree relatives
(FDRs), and second-degree relatives (SDRs).
A previous case-control study has reported on PCa risks for G84E
carriers using the UKGPCS case probands compared with healthy
controls [8]. In the present kin-cohort study, we used data on the
relatives of the probands and complex segregation analysis, and
therefore this represents an independent dataset and analysis.
All participants provided written informed consent. The study was
approved by the local medical research and ethics committees.
2.2.2. Genotyping
Genotyping was conducted using the Inﬁnium OncoArray-500 K
BeadChip (Illumina, San Diego, CA, USA), comprising single nucleotide
polymorphisms (SNPs) for genome-wide coverage and custom SNP
content selected across multiple consortia based on suspected associa-
tions with one of ﬁve common cancers [32]. The HOXB13 G84E SNP call
rate was 99.99% [33]. Mutation frequencies in the probands were
consistent with Hardy-Weinberg equilibrium proportions (exact test,
p = 0.2).
2.3. Statistical analysis
We followed male family members from age 35 until age at PCa
diagnosis, diagnosis of other cancers (excluding nonmelanoma skin
cancer), death, or age 85, whichever occurred ﬁrst. To handle incomplete
information, we imputed missing dates of birth from FDRs’ years of birth,
assuming 30 yr between subsequent generations. When age at diagnosis
was missing, we assumed that PCa occurred at age of death if available, or
otherwise at an age sampled from the observed age-at-diagnosis
distribution of men born in the same decade from the PRM arm, or at
their age at the proband's study entry, whichever was lower. We imputed
missing mortality information by sampling from historical distributions
of remaining lifespan past age 20 (males, England and Wales, 1841–2013;
Human Mortality Database, http://www.mortality.org/).
We ﬁtted genetic models wherein we assumed the effect of HOXB13
G84E to follow various modes of Mendelian inheritance. We assumed
single gene models where HOXB13 G84E was the only genetic
determinant and models that also included a polygenic component to
allow for the fact that HOXB13 G84E cannot explain all the familial
aggregation of PCa. A polygenic component is a residual term that
approximates the combined effect of a large number of unobserved low-
risk alleles, in order to capture the residual familial aggregation of PCa
not explained by HOXB13 G84E. The polygenotype was assumed to be4E Mutation and Prostate Cancer Risk. Eur Urol (2018), https://
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hypergeometric polygenic model with three alleles [34,35].
Models were parameterised in terms of the log-transformed average
RRs over the polygenotype, the logit-transformed population risk allele
frequency, and the log-transformed polygenic component's standard
deviation (SD). We constrained the average PCa incidence across all
genotypes to agree with calendar-period- and birth-cohort–speciﬁc
PCa incidences for England and Wales [36] (Cancer incidence in ﬁve
continents, volumes I–X, International Agency for Research on Cancer,
http://ci5.iarc.fr/; Ofﬁce for National Statistics, https://www.ons.gov.uk/).
Details of the model parameterisation are given in the Supplementary
material (model parameterisation). We assessed effect modiﬁcation by
allowing RRs to vary by age and birth cohort. To assess the impact of
residual family history on mutation carriers speciﬁcally, we ﬁtted models
where the polygenic component was assumed not to act on mutation
carriers or models that allowed separate polygenic SDs for carriers and
noncarriers.
To adjust for ascertainment, we used the ascertainment-assumption-
free approach [37], by modelling the conditional likelihood of observing
the family phenotypes and HOXB13 G84E mutation status, given the data
relevant to ascertainment: PCa phenotype of the proband for the PRM
and PRY families, and all family members’ PCa phenotypes for the PRS
families.
Model comparisons were based on the Akaike information criterion
(AIC) or likelihood ratio tests between nested models where appropriate.
Based on the best-ﬁtting model, we estimated absolute PCa risks based
on representative examples of family history [36]. We carried out a
number of sensitivity analyses, where we reﬁtted the model to
subgroups, and explored alternative imputation and censoring schemes
for missing ages at diagnosis.
For model ﬁtting, we used the pedigree analysis software MENDEL
(version 3.3) [38]. All other statistical analysis was performed using R
(version 3.4.0) [39].
3. Results
3.1. Systematic review and meta-analysis
The systematic review of original research articles identi-
fied 20 publications that estimated RRs of PCa for HOXB13
G84E carriers ([3–22]; Supplementary Fig. 1). RRs from
case-control studies varied between 0.95 and 33.0 (I2 = 52%,
p < 0.001; Fig. 1 and Supplementary Table 1) but differed by
case selection criteria (test for subgroup differences,
p = 0.007). A subgroup analysis restricted to unselected
case-control studies revealed significant heterogeneity
between estimates (I2 = 42%, p = 0.036; Fig. 1) and indica-
tions of funnel plot asymmetry (p = 0.12; Supplementary
Fig. 2). Based on unselected case-control studies, the
random-effect RR estimate was 3.43 (95% CI 2.78–4.23).
Omission of one outlier study yielded lower heterogeneity
between the estimates (I2 = 25%, p = 0.2; Supplementary
Table 2) but similar indications of funnel plot asymmetry
(p = 0.11; Supplementary Fig. 3), with a random-effect RR
estimate of 3.60 (95% CI 2.97–4.38; Supplementary
material, systematic review and meta-analysis).
3.2. UKGPCS families
The proband had been genotyped for HOXB13 G84E in 11 983 of
15 670 (76%) eligible families (Fig. 2). Table 1 summarises
the probands’ and family members’ characteristics. OnePlease cite this article in press as: Nyberg T, et al. Homeobox B13 G8
doi.org/10.1016/j.eururo.2018.11.015hundred and eighty-three probands (1.5%) carried the
mutation, two of whom were homozygous carriers; the
proportion of mutation carriers was highest in the family-
based PRS arm (2.6%) and lowest in the population-based PRM
arm (1.1%). In total, 45% of mutation carriers had at least one
relative who had developed PCa compared with 30% of
noncarriers; these differences were most apparent in the
young-onset PRY arm. Most participants were of European
ancestry regardless of carrier status. Age at diagnosis was
available for 62% of FDRs and 31% of SDRs with PCa; we
imputed missing ages.
3.3. Model fitting and PCa risks
Table 2 summarises the results of the model-fitting process,
and the Supplementary material (all models) describes the
detailed results for all considered models. Under both
single-gene and polygenic models, the observed family data
were most consistent with a multiplicative effect of each
mutation copy on PCa risk (single-gene multiplicative
model, AIC = 44 312.8; polygenic multiplicative model,
AIC = 40 616.1; Table 2). However, multiplicative, dominant
and general models of inheritance provided similar fit
(Supplementary Table 3), most likely due to the low number
of homozygous carriers. When a familial polygenic compo-
nent was included to allow for the residual familial effects
not explained by HOXB13 G84E mutations, the model fit
improved (Table 2). This model included calendar-period-
and cohort-specific incidences that capture the changing
PCa incidence over time. A model in which incidences from
a single calendar period (2015) were instead assumed to
apply to all family members had a worse fit (AIC = 83 526.5;
Table 2; Supplementary Table 4).
Thus, we chose the multiplicative polygenic model, with
calendar-period- and cohort-specific incidences as the main
model for all subsequent analyses. Under this model, the
average per-allele RR was 3.86 (95% CI 2.16–6.88), with a
risk allele frequency of 0.20% (95% CI 0.11–0.36%) and a
polygenic SD of 2.72 (95% CI 2.64–2.80). In this model, the
polygenic component is assumed to act multiplicatively
with HOXB13 G84E. We tested this assumption by fitting a
model that did not allow for this multiplicative effect (ie, by
assuming a polygenic SD of 0 for mutation carriers), which
had a significantly worse fit (p < 0.001). Fitting a
model with separate polygenic SDs, one for mutation
carriers and one for noncarriers, provided no significant
evidence that the magnitude of the polygenic SD differs
between mutation carriers and noncarriers (p = 0.3; Table 2;
Supplementary Table 4).
We fitted models where the RR for mutation carriers was
allowed to vary with age. None of these improved the model
fit significantly, but point estimates indicated higher RRs at
younger ages (Supplementary Table 5). The best-fitting
model with age-specific RRs was a model that allowed the
RR to vary continuously with age (p = 0.068), with estimated
RRs of 5.07 at age 50 that decreased to 3.70 at age 70
(Table 2). A model with separate RRs for mutation
carriers in the seven assumed birth cohorts showed higher
RR estimates for men born more recently and fitted4E Mutation and Prostate Cancer Risk. Eur Urol (2018), https://
Fig. 1 – Forest plot of previous estimates of the relative risk of prostate cancer for HOXB13 G84E mutation carriers, by study design and case selection
[3–22]. CI = confidence interval; RR = relative risk.
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model where a single RR was assumed to apply to all
mutation carriers (p = 0.014; Supplementary Table 5).
However, the best fitting model with cohort-specific RRs,
as determined by AIC, was a model that included an RR
parameter for men born in 1929 or earlier and a separate RR
parameter for men born in 1930 or later (AIC = 40609.6,
p = 0.004 compared with the main polygenic multiplicative
model; Table 2; Supplementary Table 5). Finally, a model
that allowed for both age- and cohort-specific RRs did
not have improved fit compared with the model withPlease cite this article in press as: Nyberg T, et al. Homeobox B13 G8
doi.org/10.1016/j.eururo.2018.11.015cohort-specific RRs (p = 0.7; Table 2). Thus, the model with
birth-cohort–specific RRs was the most parsimonious; in
this model, the estimated per-allele RR was 3.09 (95% CI
2.03–4.71) for men born in 1929 or earlier and 5.96 (95% CI
4.01–8.88) for men born in 1930 or later, with a risk allele
frequency of 0.14% (95% CI 0.09–0.21%) and a polygenic SD of
2.72 (95% CI 2.65–2.80).
Table 3 and Fig. 3 show the predicted age-specific risks of
developing PCa for a HOXB13 G84E mutation carrier born in
1960 or later, based on the most parsimonious model and
under different assumptions about PCa family history. The4E Mutation and Prostate Cancer Risk. Eur Urol (2018), https://
Fig. 2 – Flowchart of UKGPCS families included in the present study. HOXB13 = homeobox B13; PCa = prostate cancer; UKGPCS = United Kingdom Genetic
Prostate Cancer Study. aRegistered study consent date >1 yr before diagnosis. bSeven without PCa, one duplicate participant.
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for HOXB13 G84E mutation carriers, compared with 15% for
noncarriers. For a mutation carrier with an affected father,
the corresponding risk estimate ranges from 69% to 92%
depending on the father's age at diagnosis, and for a man
with two affected FDRs, the risk estimate ranges from 70% to
98%. The predicted average risks for mutation carriers born
prior to 1960 are shown in Supplementary Figure 4.
The Supplementary material (sensitivity analyses) shows
the results of our sensitivity analyses. Restriction to FDRs
produced similar results as for the main analysis (Supple-
mentary Table 6), as did alternative age imputation schemes
(Supplementary Table 7). Censoring all family members
with missing ages at diagnosis at age 0 resulted in lowerPlease cite this article in press as: Nyberg T, et al. Homeobox B13 G8
doi.org/10.1016/j.eururo.2018.11.015point estimates but similar results with respect to the
higher RR estimates for men born in 1930 and later
(Supplementary Table 7). Splitting the data by the study arm
yielded somewhat higher RR estimates when the model was
fitted using only the PRY compared with the PRM families
(Supplementary Table 6).
4. Discussion
The use of genetic information is becoming increasingly
important in urological practice, both to estimate risk and to
target treatments. It is therefore crucial to have precise risk
estimates for the known PCa susceptibility variants, includ-
ing mutations in HOXB13. We have performed a systematic4E Mutation and Prostate Cancer Risk. Eur Urol (2018), https://
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mutation carriers, and using the largest PCa case-family
dataset available to date, we have estimated age-specific PCa
risks for mutation carriers and investigated variation in these
risks by PCa family history. The pooled RR estimate from a
meta-analysis restricted to unselected case-control studies
was 3.43 (95% CI 2.78–4.23), consistent with the RR estimate
from the present study of 3.86 (95% CI 2.16–6.88). Based on
our data, the average absolute PCa risk for mutation carriers
is 62% (95% CI 47–76%) by age 85 for men born in 1960 or
later. Models that allowed for a polygenic-modifying
component on these risks fitted significantly better,
suggesting that other familial factors, that is, genetic,
environmental, and/or lifestyle-related effect modifiers that
cluster in families, modify the PCa risk for mutation carriers.
The results suggest that the PCa family history should be
taken into account in the genetic counselling process of
HOXB13 G84E mutation carriers and that a single set of
penetrance estimates would not be applicable to all
mutation carriers. We have presented absolute risk esti-
mates both applicable to the average mutation carrier in the
UK population and tailored to men with family history
configurations typically seen in family clinics.Table 1 – Characteristics of included probands and families
All 
PRMa
Total no. of families 11 983 4507 
Probands’ HOXB13
G84E status
Noncarrier Carrier Noncarrier C
11 800 183 4457 
Probands’ characteristics
Genetic ethnic ancestry
European 10 978 (93%) 174 (95%) 4087 (92%) 47 (
African 295 (2.5%) 0 (0%) 194 (4.4%) 0 (0
Asian 118 (1.0%) 1 (0.5%) 94 (2.1%) 1 (2
Mixed 49 (0.4%) 0 (0%) 31 (0.7%) 0 (0
Unknown 360 (3.1%) 8 (4.4%) 51 (1.1%) 2 (4
Age at prostate cancer diagnosis (yr)
44 104 (0.9%) 3 (1.6%) 11 (0.2%) 0 (0
45–54 2232 (19%) 43 (23%) 263 (5.9%) 2 (4
55–64 6162 (52%) 91 (50%) 1317 (30%) 15 (3
65–74 2612 (22%) 37 (20%) 2219 (50%) 29 (
75–84 684 (5.8%) 8 (4.4%) 647 (15%) 4 (8
85d 6 (0.1%) 1 (0.5%) 0 (0%) 0 (0
Median
(interquartile
range)
59 (56–66) 58 (54.5–64.5) 67 (62–72) 67.5
Mean
(standard
deviation)
60.5 (7.7) 59.5 (8.0) 66.8 (7.3) 66.2
Year of prostate cancer diagnosis
1994 614 (5.2%) 9 (4.9%) 463 (10%) 7 (1
1995–1999 1158 (9.8%) 20 (11%) 703 (16%) 9 (18
2000–2004 3009 (26%) 40 (22%) 1304 (29%) 12 (
2005–2009 3728 (32%) 60 (33%) 1321 (30%) 15 (3
2010–2014 3291 (28%) 54 (30%) 666 (15%) 7 (1
Family characteristics
No. of 1st- and 2nd-degree relatives with prostate cancer below age 85 per fami
0 8267 (70%) 101 (55%) 3765 (84%) 41 (
1 2435 (21%) 51 (28%) 553 (12%) 6 (1
2 807 (6.8%) 26 (14%) 106 (2.4%) 3 (6
3 291 (2.5%) 5 (2.7%) 33 (0.7%) 0 (0
Please cite this article in press as: Nyberg T, et al. Homeobox B13 G8
doi.org/10.1016/j.eururo.2018.11.015We used calendar-period- and birth-cohort–specific
population PCa incidences that account for the rising
population incidences over time. This may be particularly
important given the recent more widespread use of
prostate-specific antigen (PSA) testing. Despite this, RR
estimates for mutation carriers were higher in more recent
birth cohorts, over and above the general rise in population
incidences. For example, the predicted PCa risks by age
85 are 19%, 54%, and 62% for mutation carriers born in
1909 or earlier, during 1930–1939, and in 1960 or later,
respectively. This could reflect a true birth cohort effect,
resulting from changes in environmental or lifestyle factors
over time. Alternatively, it may also result from the
possibility that men with affected relatives may be more
likely to request a PSA test and that the increased
availability of PSA testing thus might have resulted in
clustering of PCa diagnoses in more recent generations. One
way to evaluate this potential source of bias would be to
assess the association with the risk of aggressive or fatal PCa
only. Unfortunately, PCa in relatives was reported by the
probands and data on tumour aggressiveness in relatives
were not available to us. We note, however, that previous
studies revealed at most minor differences in tumourAscertainment group
PRSb PRYc
869 6607
arrier Noncarrier Carrier Noncarrier Carrier
50 846 23 6497 110
94%) 715 (85%) 21 (91%) 6176 (95%) 106 (96%)
%) 4 (0.5%) 0 (0%) 97 (1.5%) 0 (0%)
.0%) 3 (0.4%) 0 (0%) 21 (0.3%) 0 (0%)
%) 2 (0.2%) 0 (0%) 16 (0.2%) 0 (0%)
.0%) 122 (14%) 2 (8.7%) 187 (2.9%) 4 (3.6%)
%) 1 (0.1%) 0 (0%) 92 (1.4%) 3 (2.7%)
.0%) 10 (1.2%) 0 (0%) 1959 (30%) 41 (37%)
0%) 399 (47%) 10 (43%) 4446 (68%) 66 (60%)
58%) 393 (46%) 8 (35%) 0 (0%) 0 (0%)
.0%) 37 (4.4%) 4 (17%) 0 (0%) 0 (0%)
%) 6 (0.7%) 1 (4.3%) 0 (0%) 0 (0%)
 (62–70) 65 (62–68) 65 (62.5–71.5) 57 (54–58) 56 (52–58)
 (6.6) 65.4 (5.1) 67.4 (7.3) 55.6 (3.8) 54.8 (4.4)
4%) 52 (6.1%) 0 (0%) 99 (1.5%) 2 (1.8%)
%) 113 (13%) 3 (13%) 342 (5.3%) 8 (7.3%)
24%) 214 (25%) 6 (26%) 1491 (23%) 22 (20%)
0%) 236 (28%) 10 (43%) 2171 (33%) 35 (32%)
4%) 231 (27%) 4 (17%) 2394 (37%) 43 (39%)
ly
82%) 3 (0.4%)e 0 (0%) 4499 (69%) 60 (55%)
2%) 418 (49%) 11 (48%) 1464 (23%) 34 (31%)
.0%) 303 (36%) 9 (39%) 398 (6.1%) 14 (13%)
%) 122 (14%) 3 (13%) 136 (2.1%) 2 (1.8%)
4E Mutation and Prostate Cancer Risk. Eur Urol (2018), https://
Table 1 (Continued )
All Ascertainment group
PRMa PRSb PRYc
Total no. of families 11 983 4507 869 6607
Probands’ HOXB13
G84E status
Noncarrier Carrier Noncarrier Carrier Noncarrier Carrier Noncarrier Carrier
11 800 183 4457 50 846 23 6497 110
Male 1st- and 2nd-degree relatives’ characteristics
Total no.
with prostate
cancer below
age 85/total
no. (%)
4572/78 583
(5.8%)
115/1315
(8.7%)
765/21 041
(3.6%)
11/240
(4.6%)
1321/8020
(16%)
40/235
(17%)
2486/49 522
(5.0%)
64/840
(7.6%)
Age at prostate cancer diagnosis
44 13 1 2 0 5 0 6 1
45–54 188 4 17 1 51 0 120 3
55–64 766 22 90 0 316 13 360 9
65–74 940 28 130 4 320 7 490 17
75–84 515 11 77 1 133 6 305 4
85f 104 1 31 0 26 0 47 1
Unknown 2150 49 449 5 496 14 1205 30
Median
(interquartile
range)
70 (63–78) 70 (62–76) 71 (65–79) 69.5 (63–76.5) 68 (62–76) 65 (62–77) 71 (63–78) 70 (63–76)
Mean
(standard
deviation)
71.2 (10.7) 68.5 (10.6) 71.9 (10.6) 69.0 (12.7) 68.9 (10.1) 68.3 (9.3) 70.3 (10.9) 68.5 (11.0)
Year of birthg
1909 809/22 644 (3.6%) 17/363 (4.7%) 231/8074 (2.9%) 1/87 (1.1%) 247/2662 (9.3%) 9/86 (10%) 331/11 908 (2.8%) 7/190 (3.7%)
1910–1919 815/10 392 (7.8%) 23/169 (14%) 146/2443 (6.0%) 2/40 (5.0%) 219/1079 (20%) 3/31 (9.7%) 450/6870 (6.6%) 18/98 (18%)
1920–1929 1142/9516 (12%) 25/177 (14%) 164/1592 (10%) 2/17 (12%) 203/573 (35%) 7/14 (50%) 775/7351 (11%) 16/146 (11%)
1930–1939 873/5040 (17%) 21/83 (25%) 129/1432 (9.0%) 3/15 (20%) 324/561 (58%) 7/10 (70%) 420/3047 (14%) 11/58 (19%)
1940–1949 660/4421 (15%) 19/78 (24%) 74/1189 (6.2%) 2/14 (14%) 266/551 (48%) 13/21 (62%) 320/2681 (12%) 4/43 (9.3%)
1950–1959 237/4519 (5.2%) 7/77 (9.1%) 17/1136 (1.5%) 1/14 (7.1%) 56/466 (12%) 1/11 (9.1%) 164/2917 (5.6%) 5/52 (9.6%)
1960 36/21 949 (0.2%) 3/365 (0.8%) 4/5120 (0.1%) 0/53 (0%) 6/2123 (0.3%) 0/61 (0%) 26/14 706 (0.2%) 3/251 (1.2%)
HOXB13 G84E statush
Noncarrier 431/469 (92%) 5/6 (83%) 47/56 (84%) 0/1 (0%) 183/194 (94%) 1/1 (100%) 201/219 (92%) 4/4 (100%)
Carrier 5/5i (100%) 8/9 (89%) 1/1 (100%) 2/2 (100%) 2/2i (100%) 4/5 (80%) 2/2 (100%) 2/2 (100%)
Not genotyped 4136/78 104 (5.3%) 102/1301 (7.8%) 717/20 980 (3.4%) 9/238 (3.8%) 1136/7826 (15%) 35/229 (15%) 2283/49 298 (4.6%) 58/834 (7.0%)
HOXB13 = homeobox B13.
a Population-based arm: men diagnosed or treated at the Royal Marsden NHS Foundation Trust at any age.
b Family-based arm: men from families with at least two prostate cancer cases, one of whom were diagnosed at age 65 or earlier, or three family members
diagnosed at any age.
c Young-onset arm: men diagnosed at 60 or earlier.
d Families in the family-ascertained PRS arm in which the proband had prostate cancer above the censoring endpoint of age 85 were retained in the study, in line
with the cohort's ascertainment criteria that allow entry of families where at least three members were diagnosed at any age.
e Fulfilled inclusion criteria for the PRS arm by having third-degree or more distant relatives with prostate cancer.
f Men with prostate cancer at or above age 85 were censored at age 85. Therefore, they are not included in the total number of men with prostate cancer
elsewhere in this table.
g The table shows years of birth after imputation of missing values using the years of birth of each individual's first-degree relatives and assuming a gap of 30 yr
between subsequent generations.
h Genotyping data were available for 489 male relatives, of whom 14 were heterozygous mutation carriers.
i Includes two mutation carriers from the same family.
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G84E mutation [5–12,14,16,20,21] and that familial RRs of
PCa estimated on the basis of the UKGPCS population-based
arm were in line with the estimates from other large
epidemiological studies [40].
Previous studies reported higher RRs at younger ages
[3,5,6,10]. We found some evidence of decreasing RRs with
age, but a model with both age- and cohort-specific RRs did
not fit significantly better than a model with only cohort-
specific RRs and estimated an adjusted per-year-of-age RR
of 1.00 (95% CI 0.98–1.01). This could however be due to lackPlease cite this article in press as: Nyberg T, et al. Homeobox B13 G8
doi.org/10.1016/j.eururo.2018.11.015of power, and our results suggest that it is difficult to
distinguish between decreasing age-specific RRs and
increasing risks with more recent birth cohort because
the effects are confounded. Only one other study investi-
gated variation in RRs by birth cohort but did not observe
significant differences [13]; however, it was based on only
19 families with mutations.
The meta-analysis of previous studies revealed signifi-
cant differences in reported RRs by case selection, in
particular, when case selection depended on family history.
This is consistent with the results of the present analysis4E Mutation and Prostate Cancer Risk. Eur Urol (2018), https://
Table 2 – Models for the prostate cancer incidence fitted using complex segregation analysis
Main effects models by assumed inheritance
Model Log likelihood No. of
parameters
AIC Likelihood ratio
test p value
HOXB13 G84E RR 95% CI Minor allele
frequency (%)
95% CI Polygenic
standard deviation
95% CI
Sporadic 22 182.9 1 44 367.8 – 1.00a 0.77 0.67–0.89 0.00a
Multiplicative 22 154.4 2 44 312.8 <0.001b Per allele 3.79 3.00–4.80 0.18 0.13–0.24 0.00a
Polygenic 20 315.6 2 40 635.2 <0.001b 1.00a 0.77 0.67–0.89 2.73 2.65–2.81
Polygenic multiplicative 20 305.0 3 40 616.1 <0.001c Per allele 3.86 2.16–6.88 0.20 0.11–0.36 2.72 2.64–2.80
Polygenic multiplicative model, alternative ﬁts
Model Log likelihood No. of
parameters
AIC Likelihood
ratio test p value
Group Per-allele
RR
95% CI Minor allele
frequency (%)
95% CI Polygenic
standard deviation
95% CI
Assuming latest available population
incidence (2015) for all birth cohorts
41760.2 3 83 526.5 – 4.20 3.49–5.04 0.14 0.10–0.18 3.26 3.23–3.30
Assuming that polygenic component
does not act on mutation carriers
20 330.2 3 40 666.4 – 9.73 7.74–12.2 0.09 0.07–0.11
Noncarriers 2.72 2.64–2.80
G84E carriers 0.00a
Assuming separate polygenic standard
deviation for mutation carriers
20 304.4 4 40 616.8 0.3d; <0.001e 4.98 2.74–9.05 0.16 0.09–0.29
Noncarriers 2.72 2.64–2.80
G84E carriers 3.28 2.63–4.09
Polygenic multiplicative models, RR modiﬁed by age and/or birth cohort
Model Log likelihood No. of
parameters
AIC Likelihood ratio
test p value
Group Per-allele
RR
95% CI Minor allele
frequency (%)
95% CI Polygenic
standard deviation
95% CI
Age-speciﬁc RR: per year of age
(log-linear model)f,g
20 303.4 4 40 614.8 0.068d 0.18 0.11–0.31 2.72 2.64–2.80
Baseline (age 70) 3.70 2.23–6.14
Per year of age 0.98 0.97–1.00
Birth-cohort–speciﬁc RR:
dichotomous birth cohort groupsh
20 300.8 4 40 609.6 0.004d 0.14 0.09–0.21 2.72 2.65–2.80
Born 1929 3.09 2.03–4.71
Born 1930 5.96 4.01–8.88
Age- and birth-cohort–speciﬁc RRi 20 300.7 5 40 611.3 0.020j; 0.6k 0.14 0.09–0.21 2.72 2.65–2.80
Born 1929 (age 70) 3.13 1.96–5.01
Born 1930 (age 70) 5.71 3.71–8.78
Per year of age 1.00 0.98–1.01
AIC = Akaike information criterion; CI = conﬁdence interval; HOXB13 = homeobox B13; RR = relative risk.
a Constrained to constant value.
b Compared with sporadic model.
c Compared with polygenic model.
d Compared with polygenic multiplicative model.
e Compared with polygenic multiplicative model where the polygenic component does not act on mutation carriers.
f The model was specified as ln RRðtÞ ¼ a0 þ a1  ðt  70Þ for men at age t, where a0 corresponds to the estimated RR at age 70 and a1 the change in RR per year of age; see the Supplementary material (model
parameterisation).
g Best fitting model with age-specific RR as selected by AIC; all considered models are given in the Supplementary Table 5.
h Best fitting model with birth-cohort–specific RR as selected by AIC; all considered models are given in the Supplementary Table 5.
i The model was specified as ln RRðt; kÞ ¼ g1929  1 k2birth cohort group1929f g þ g1930  1 k2birth cohort group1930f g þ a t  70ð Þ for men in birth cohort k at age t, where g 1929 and g 1930 correspond to the estimated RR at age
70 for men born in 1929 or earlier and in 1930 or later, respectively, and a is the change in RR per year of age; see the Supplementary material (model parameterisation).
j Compared with polygenic multiplicative model with log-linear age-specific RR.
k Compared with polygenic multiplicative model RR specific to birth cohorts 1929/1930.
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Table 3 – Predicted cumulative prostate cancer risks for a 35-yr-old man born in 1960 or later and carrying a single copy of the HOXB13 G84E
mutation, as estimated by the most parsimonious model, by varying family history of prostate cancer
Family history Prostate cancer risk for consultand by age (yr)
40 45 50 55 60 65 70 75 80 85
Average familial riska 0.0% 0.2% 1% 3% 9% 17% 29% 42% 53% 62%
Father unaffected at age 80, grandfather
unaffected at age 80
0.0% 0.1% 0.6% 2% 6% 14% 25% 38% 50% 60%
Father unaffected at age 80, grandfather
had prostate cancer at age 80
0.0% 0.2% 0.9% 3% 9% 19% 33% 48% 60% 70%
Father had prostate cancer at age 80,
grandfather had prostate cancer at age 80
0.0% 0.3% 1% 5% 12% 25% 40% 56% 69% 78%
Father had prostate cancer at age (yr)
40 0.1% 0.8% 4% 13% 28% 47% 65% 79% 87% 92%
50 0.1% 0.8% 4% 13% 28% 47% 65% 79% 87% 92%
60 0.1% 0.7% 4% 12% 25% 43% 61% 75% 84% 89%
70 0.0% 0.4% 2% 7% 16% 29% 46% 60% 71% 79%
80 0.0% 0.2% 1% 4% 10% 21% 35% 49% 60% 69%
Brother had prostate cancer at age (yr)
40 0.1% 0.9% 5% 14% 29% 48% 65% 78% 86% 90%
50 0.1% 0.9% 4% 14% 28% 47% 63% 77% 85% 89%
60 0.1% 0.5% 3% 9% 20% 36% 53% 68% 77% 84%
70 0.0% 0.3% 1% 5% 13% 25% 40% 55% 67% 75%
80 0.0% 0.2% 0.9% 3% 9% 18% 31% 44% 56% 66%
Prostate cancer risk for consultand by age 85 yr
Brother had prostate cancer at age (yr)
40 50 60 70 80
Father had prostate cancer at age (yr)
40 98% 98% 97% 93% 90%
50 98% 98% 96% 93% 90%
60 98% 98% 95% 91% 88%
70 94% 93% 90% 84% 78%
80 90% 89% 84% 77% 70%
HOXB13 = homeobox B13.
In all family history scenarios, consultands and their brothers were assumed to be born in 1960 or later, fathers were assumed to be born in 1930–39, and
grandfathers were assumed to be born in 1909 or earlier.
a That is, ignoring family history information.
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PCa family history and suggest that model-based estimates,
which consider family history similar to those presented
here, may be more appropriate for counselling purposes.
Furthermore, among unselected case-control studies, we
found heterogeneity between published RR estimates as
well as indications of funnel plot asymmetry. This may
reflect differences in study design, selection criteria,
adjustment variables used in the analysis, and/or publica-
tion bias [41], and caution is required in the use of the
resulting pooled estimate.
Based on the most parsimonious model, approximately
one in 360 individuals carries the HOXB13 G84E mutation in
the UK. This is consistent with previous UK and Western
European population estimates [4,8,9]. Based on this
mutation frequency estimate and the RR estimate for
men born in 1930 or later and assuming a familial RR in
FDRs of 2.5 [42], HOXB13 G84E accounts for approximately
3.6% of the excess familial risk of PCa [43].
Family-based studies can produce high precision risk
estimates, due to the aggregation of likely mutation carriers.
However, because individuals are ascertained through
affected family members and thus generally are at a higherPlease cite this article in press as: Nyberg T, et al. Homeobox B13 G8
doi.org/10.1016/j.eururo.2018.11.015than average risk of disease, adjustment for the ascertain-
ment is needed to avoid biased estimates [24]. Among the
previous family-based studies on HOXB13 G84E and PCa risk
[3,10,13,19], only two adjusted for the ascertainment proce-
dure or the relatedness between subjects [13,19]. Here, we
adjusted for ascertainment using the ascertainment-assump-
tion-free approach, which gives unbiased estimates provided
that all information related to the ascertainment is available,
however at the cost of somewhat reduced precision [37].
Strengths of our study include the large sample size and
the use of the kin-cohort study design, allowing the use of
cancer history information in relatives of mutation carriers.
The dataset included both families ascertained through
population-based PCa cases and additional families
enriched for a young age at diagnosis or a family history
of PCa. This provided information on mutation carriers with
a wide range of ages at diagnosis and family history
configurations, which enabled us to model the variation in
risks by family history and other characteristics. Our model-
based estimates would thus be applicable to not only
mutation carriers identified in family clinics, but also
carriers identified through population-based mutation
screening programmes.4E Mutation and Prostate Cancer Risk. Eur Urol (2018), https://
Fig. 3 – Predicted cumulative prostate cancer risks for a 35-yr-old man born in 1960 or later and carrying a single copy of the HOXB13 G84E mutation,
as estimated by the most parsimonious model, with (A) average (unknown) prostate cancer family history, with a 95% confidence interval; (B) a father
diagnosed with prostate cancer at varying ages; (C) a brother diagnosed with prostate cancer at varying ages; and (D) a father and a brother diagnosed
with prostate cancer at varying ages. In all family history scenarios, consultands and their brothers were assumed to be born in 1960 or later, and
fathers were assumed to be born in 1930–39. HOXB13 = homeobox B13.
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family history, which can be inaccurate, particularly for
more distant relatives [44]. We evaluated the impact of
including information on SDRs on the results by refitting the
model using only FDRs, and the estimates remained similar.
Furthermore, since men were unaware of their mutation
status at study entry, no differential reporting of family
history by mutation status should be expected. We imputed
missing ages at diagnosis in relatives using the age
distribution in the population-based families, which may
approximate the age-at-diagnosis variation of the general
population. While imputation adds uncertainty, alternative
imputation schemes based on external population inci-
dence information or those that instead allowed study-
arm–specific imputations produced similar results. When
all relatives with unknown ages were censored, the
estimated RRs and polygenic SD were lower and likely
underestimated. However, the differences in RR estimate
sizes between the birth cohorts remained, indicating that
these findings are not driven by the assumed imputation
scheme. In subgroup analyses, the families ascertained
through a young case generally showed higher RR estimates
compared with the population-based families, which mayPlease cite this article in press as: Nyberg T, et al. Homeobox B13 G8
doi.org/10.1016/j.eururo.2018.11.015reflect a residual bias even after the ascertainment
adjustment. Confidence intervals were overlapping and
apparent subgroup differences could be due to chance, but
we cannot exclude the possibility that imperfect ascertain-
ment adjustment may have resulted in somewhat over-
estimated RRs. Finally, although a multiplicative model
showed best fit, the low number of homozygous mutation
carriers complicates distinguishing multiplicative from
dominant or general models of inheritance.
5. Conclusions
We have shown that the risk of PCa for HOXB13 G84E
mutation carriers varies by PCa family history and by birth
cohort. The family-history- and birth-cohort–specific risks
may be useful in the counselling of mutation carriers. The
current estimates should be incorporated into comprehen-
sive risk prediction models, which also consider other
known genetic predisposition variants including low-risk
common susceptibility alleles identified through genome-
wide association studies, to enable tailored clinical risk
prediction of this highly polygenic disease.4E Mutation and Prostate Cancer Risk. Eur Urol (2018), https://
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